By Sharena Rice, contributing editor
August 12, 2026 | Money in medical neurotechnology is pulling toward two poles at once, and the middle appears to be thinning. At one end, a small cluster of platform companies is absorbing financing at a scale the field has never seen. At the other, private capital is moving downstream into the clinics that deliver treatment. What sits between those poles, the broad tail of device companies still building toward first-in-human and clearance, is being asked to get creative or survive while nondilutive funding is harder to predict.
The Non-Dilutive Floor Is Dropping
Non-dilutive translation funding has long served as a type of bridge across the device valley of death, the stretch between a working prototype and a commercially fundable asset. NIH’s Blueprint MedTech program was built for that crossing, moving medical devices from late-stage development toward first-in-human readiness with nondilutive capital.
Its most recent renewal is landing below what many in the field hoped. Specific award totals for the coming cycle are not yet public. The direction, though, is consistent with a broader federal signal. NIH obligated $402 million across 601 multiyear grants in the first half of FY 2026, more than four times the grant count and five times the dollar total of the same window in FY 2024. This front-loads multi-year commitments into a single fiscal year’s obligations, which leaves less budget available for new project starts and competitive renewals. NIH’s own trajectory (5,564 fewer grants awarded in FY 2025 than FY 2024, with FY 2026 projected to fall roughly 970 grants further behind if the trend holds) shows the squeeze is already compounding rather than one-time. For a device company counting on a translation award to reach its next value inflection, the practical effect may be a narrower, more competitive bridge at precisely the moment the private markets are also selective.
The Private-Capital Barbell
Venture dollars in neurotech look abundant in aggregate, but they are not evenly distributed. Brain-computer interface companies captured roughly three quarters of neurotechnology deal capital in a recent multi-quarter window, 76%, against just 36% of deal count. This is the first sign the field runs on a small number of outsized rounds rather than broad-based investment. Neuralink’s $650 million Series E, closed June 2025, is the largest deal by itself, 32% of all disclosed capital in the dataset. Add Merge Labs’ $252 million seed round (January 2026, OpenAI-adjacent and Sam Altman-linked investors) and BrainCo’s $286.3 million growth round (January 2026, the largest BCI raise outside the US), and the top three account for 58%. Add Synchron’s $200 million Series D and Science Corporation’s $230 million Series C and the top five reach 79%. These five companies, with five distinct technical approaches, captured four out of every five disclosed dollars in the category over two years.
The barbell appears in round size too, within BCI specifically. Eight of the sixteen disclosed BCI rounds were above $50 million and six were above $100 million. Strip those eight rounds out and total disclosed BCI capital falls from $2.06 billion to $211.69 million, meaning sub-$50-million BCI deals account for just over 10% of category capital. Those smaller rounds are still real, disclosed, venture-backed companies working on brain interfacing specifically: INBRAIN Neuroelectronics’ $50 million Series B (graphene-based implantable electrodes), Precision Neuroscience’s $102 million Series C (minimally invasive cortical interface), Axoft’s $55 million Series A (soft implantable neural-interface materials), Subsense’s two rounds totaling $27 million (non-surgical nanoparticle-based interface).
The checks are getting larger. Yet a few firms dominate in scoring the checks.
The Downstream Bet on Verified Delivery
Another revealing move is where else in the neuro ecosystem capital is moving. Rather than funding earlier-stage technology, private equity and growth investors are buying into the delivery layer, the sites where care happens.
Cathay Capital launched Ascendia Autism Care at the end of June 2026, anchored by a founding affiliate that already runs 20 centers across eight states, with de novo expansion planned across every market over 24 months. Applied behavior analysis is reimbursed by commercial insurance and Medicaid in all 50 states, which gives the platform a defined revenue base from day one. In interventional psychiatry, NRx’s HOPE Therapeutics has been rolling up ketamine and TMS clinics into a single network through a series of acquisitions. The common thread is not a novel device. It is a proven point of care with billable procedures and, increasingly, a research backbone that lets the platform generate clinical evidence.
What This Says About How the Field Prices Risk
Read together, these moves describe a coherent risk posture. Capital is favoring verified points of care over unproven pipelines, and where it does fund technology, the funding tends to concentrate on a few platforms poised to look like category winners. The reward is being paid for scale and for proximity to reimbursed delivery.
For a device company caught in the gap, the strategic plays narrow to a few honest options: position yourself as the pick-and-shovel supplier or partner to the platforms drawing the mega-rounds, where the buyer has capital and a clear integration need. Be part of a delivery network and let the point of care become the site of both revenue and evidence generation. Impose milestone discipline tight enough and early enough to reach a fundable inflection on a thinner runway than previous years’ plans assumed. Find other creative means. Waiting for the translation-funding environment to loosen is not really a strategy.
The uncomfortable reality is that the middle path, the steady-headcount company directly advancing a promising device one indication at a time on an incremental timeline, is a more challenging position to sustain than in prior years. The capital has largely moved to the ends of the barbell to offset risk.
